Prostate Cancer

The addition of apalutamide to androgen deprivation therapy is well tolerated and significantly improves survival while maintaining health-related quality of life in men with prostate cancer.

Hyperbaric oxygen therapy can relieve symptoms of late radiation cystitis in patients who underwent radiotherapy of the pelvic region for prostate cancer.

The agency granted breakthrough therapy designation to niraparib for the treatment of men with BRCA1/2-mutant positive metastatic castration-resistant prostate cancer.

Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.

The findings of a trial presented at ESMO 2019 may be a breakthrough when it comes to molecularly targeted treatment for prostate cancer.

Mushrooms reportedly have anticancer and antitumor properties, so researchers in Japan investigated to see if there was a link between mushroom intake and prostate cancer.

STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.

How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out.

Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.

A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.

Researchers looked at data from the Surveillance, Epidemiology, and End Results database to see if there has been any increase in the use of active surveillance or watchful waiting when it comes to low-risk prostate cancer.

The study compared PET/CT tracers over 18F-fluciclovine when it comes to the localization of biochemical recurrence of prostate cancer following radical prostatectomy.

Test your knowledge of metastatic prostate cancer with this month's quiz.

Researchers conducted gene expression analyses on prostate cancer tumor samples from World Trade Center first responders and general population patients to see if there were any differences between the two.

Dr. Kittles discusses the race-based health disparities in prostate cancer, and one genetic-environmental crossover that is clinically significant.

How much do you know about molecular risk and prognostic biomarkers in prostate cancer? Take our latest quiz to test your knowledge.

A new study used two patient-reported measures of sexual function following radical prostatectomy to assess sexual interest and satisfaction in men with prostate cancer.

Researchers compared several glucocorticoid regimens, given in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer.

In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.

In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.

An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.

The PAIREDCAP trial looked at different biopsy approaches to see which has the highest cancer detection rate for prostate cancer.

A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for metastatic castration-resistant prostate cancer.

Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.

The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer.